Navigation Links
Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
Date:2/15/2012

NEW YORK, Feb. 15, 2012 /PRNewswire/ -- The Lupus Research Institute (LRI) today awards 12 "Novel Research Grants" to jumpstart discovery in lupus by supporting original, highly promising ideas from some of the country's most creative scientists. Studies will look at why lupus turns the body's immune system against itself and pioneer strategies for new treatment development.   

The new awards represent diverse disciplines, from inflammation and medical imaging to evolutionary biology and the emerging field of epigenetics, bringing new talent and new approaches to lupus. Rigorous peer-review of 106 applications involved LRI's scientific advisors and over 90 lupus experts nationwide; $3.6 million was granted. Award-winning projects represent the best of the best, with potential to achieve significant results and accelerate drug discovery.

"What distinguishes the Lupus Research Institute is our insistence on funding only novel ideas rather than furthering established concepts," said Margaret Dowd, LRI President and CEO. "Our success in delivering pivotal discoveries proves that openness to inventive science works. As one advisor eloquently noted, 'great science cannot be managed; it must be imagined.'"

Championing human lupus biology, the LRI aims to speed the pace of meaningful findings in the human disease, providing fresh insights to directly inform new treatment and diagnostic development. Six investigators will work directly with patients using their blood cells, genetic information, and brain images to ask fundamental questions about the lupus immune system previously only approached in animal models.

"The Lupus Research Institute is uniquely positioned to identify novel high-risk projects that offer great return for the lupus community," noted world-leading immunologist Dr. William Paul, LRI Scientific Advisory Board Chairman and Nati
'/>"/>

SOURCE Lupus Research Institute
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
2. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
3. Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus
4. Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly $2 Billion in 2018
5. Promise of a New Lupus Treatment Is a Groundbreaking Achievement
6. Lupus Research Institute: Benlysta(TM) Trial Results in an Historic Research Breakthrough and Victory for People With Lupus
7. deCODE Announces Agreement With Pfizer to Search for Variants in the Human Genome That Confer Risk of Systemic Lupus Erythematosis
8. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
9. Human Genome Sciences Europe Moves to the Cloud With Veeva CRM to Support New Lupus Treatment
10. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
11. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Jan. 14, 2014   Kinaxis ®, provider of RapidResponse ... sales and operations planning ( S&OP ) service, is proud ... , which will be held at the Hilton San Diego ... Kinaxis customer Elisabeth Kaszas , Director of Supply Chain ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly ... this time period, doctors did not know that they needed ... death of vulnerable patients. In the same way, medical interns ... unwittingly transmitting herpes viruses to their patients. The CBCD explains. ...
(Date:1/14/2014)... January 14, 2014 Holloway America today ... of material test reports (MTRs) for all pressure vessels ... test results is particularly important for equipment that must ... MTR Library features search functionality that allows authorized users ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Data Reported by Roche at 69th Scientific Sessions , ... Inc. (Nasdaq: VIAP ), a biotechnology company ... of cardiovascular and metabolic disease, announced today that preclinical ... inhibitors will be presented in a poster presentation at ...
... , Thursday, June 11th, 10:00 a.m. EDT , , ... ) announced today that the Company President and Chief Executive Officer, ... on Thursday, June 11th, 2009 at 10:00 a.m. EDT, to report ... a quarterly update of the Company. , , This call ...
... initial steps towards producing Influenza A (H1N1) VLP vaccine for ... 4 Novavax, Inc. (Nasdaq: NVAX ) and ... National Institute of Allergy and Infectious Diseases (NIAID), National Institutes ... the evaluation of a virus-like particle (VLP) vaccine candidate against ...
Cached Biology Technology:VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 2VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 3VIA Pharmaceuticals' DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation 4Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 2Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 3Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus 4
(Date:4/23/2014)... Wash. -- Like a hungry diner ripping open a ... into electricity must tear open a hydrogen molecule. Now ... holding onto the two halves of its hydrogen feast. ... how to make the catalyst work better for alternative ... scientists have shown precisely where the hydrogen halves end ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23 2014) ... human neural stem cells (hNSCs) into the brains ... differentiation after 22 and 24 months found that ... months and did not cause tumors. , The ... of Cell Transplantation but is currently ...
(Date:4/23/2014)... evidence of an interaction between prenatal smoking and ... children, especially in girls. , "The interesting issue ... smoking will have behavioral problems. Some might, ... Professor at Sam Houston State University, College of ... "One possible explanation for this is that ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Study finds long-term survival of human neural stem cells transplanted into primate brain 2Genetics risk, prenatal smoking may predict behavioral problems 2
... we are strong and healthy and then we weaken and die ... about. But, in nature, the phenomenon of ageing shows an unexpected ... The University of Southern Denmark. Not all species weaken ... get stronger and less likely to die with age, while others ...
... The addition of a monoclonal antibody called gemtuzumab combined ... the risk of relapse and increase rates of disease-free ... Post-treatment relapse rates are a major indicator of potential ... The study (abstract #355) evaluated a total of 1,022 ...
... EPA grant, NJIT established its Technical Assistance to Brownfield ... allow NJIT to continue to provide communities with scientific, ... Specifically, the grant allows the NJIT TAB team to ... Mid-Atlantic region. NJIT TAB is comprised of planners, environmental ...
Cached Biology News:Surprising diversity in aging revealed in nature 2Surprising diversity in aging revealed in nature 3Targeted treatment can significantly reduce relapse in children with AML leukemia 2EPA awards $1 million grant to NJIT's Brownfield program 2
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Recombinant Rhesus Monkey IFN-Alpha...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
Biology Products: